You may know hepatitis B and C (HBV and HCV) are serious viral infections that can damage the liver and lead to liver cancer. But did you know that most people with HBV and HCV aren’t aware that they are infected? According to the World Health Organization (WHO), only 11% of all people estimated to have HBV know their status. For HCV, it's estimated that 1 in 5 people with HCV are aware of the infection. Because so many living with chronic HBV and HCV show so few signs of infection, these conditions may go unnoticed for decades, often until permanent damage has been done to the liver. How can you detect viruses that rarely, outwardly show their faces? It all starts with diagnostic tools that pinpoint the infections. Fighting Silent Killers Hepatitis B and C are far more common than many people think. Around the world, approximately 296 million people are living with chronic HBV infection and 58 million people are living with chronic HCV infection. The burden of HBV infection is highest in the Western Pacific and Africa regions, where 116 million and 81 million people, respectively, are chronically infected. A significant number of those will develop chronic liver damage (also called cirrhosis) or potentially liver cancer. There is good news. Tests are available to diagnose HBV and HCV infection so that treatment can be provided, potential transmissions prevented and the progression to fatal liver disease stopped. Rapid point-of-care tests are available for screening, enabling testing in decentralized settings in remote areas. Infants can be protected from HBV through a safe and effective vaccine. Antiviral medicines for HBV can slow the progression of cirrhosis, reduce the chance of liver cancer and improve long-term survival. Antiviral medicines can cure more than 95% of people with HCV, reducing the associated health risks. In May 2016, the WHO set a goal to eliminate HCV and HBV as a public health threat by 2030 through increased access to testing and treatment. Making the WHO 2030 Goal Possible Combining testing and treatment efforts to combat hepatitis makes ending the epidemic feasible: Access to diagnostics: Unfortunately, testing is not available everywhere. There is work to be done to expand access to testing and treatment in decentralized settings to reach more people more easily. Incomplete diagnosis: Some people who test positive for hepatitis antibodies do not get needed follow-up tests to confirm active infection. Reducing mother-to-child transmission: Without preventive interventions, the risk of transmission from mother to child ranges from 70% to 90% for mothers with high HBV viral load. Therapies during pregnancy and birth dose vaccination within 24 hours are critical for reducing transmission to a newborn baby. Treatment availability: In 2019, of those living with chronic infections globally, only a small portion received treatment. 6.6 million people were on treatment for HBV, and 9.4 million people were on treatment for HCV. 'We're constantly searching for new ways to help improve the tests available to diagnose people living with viral hepatitis. Part of that process involves studying the barriers to access testing that hinders eliminating the epidemic,' said Gavin Cloherty, Ph.D., head of infectious disease research at Abbott and the Pandemic Defense Coalition.